They are of two types, Dihydropyridines and Non-dihydropyridines.

Said optically pure 1,4-dihydropyridines can then be subjected to desulphuration and to different transformations to give other enantiomerically pure and therapeutically useful 1,4-dihydropyridines.

The invention also includes methods of producing the said dihydropyridines.

This invention provides novel oxathiepino[6,5-b]dihydropyridines.

The compounds are substituted dihydropyridines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of C5a receptors.

The present invention is directed to θ6 metal complexes of the arene group of 4-aryl-1,4-dihydropyridines.

The present invention also relates to novel 1,4-dihydropyridines with cardiovascular activity.

Eighteen RCTs (14 dihydropyridines, 4 non-dihydropyridines) with a total of 141,807 participants were included.

Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites.

Hypersensitivity to amlodipine or to any other dihydropyridines,

Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites.

Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites.

Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites.

Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites.

Experimental data suggest that S-amlodipine binds to both dihydropyridine and nondihydropyridine binding sites.